Drugs / octreotate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02358356 | Nov 2015 → Oct 2021 | pancreatic neuroendocrine tumor, small intestine neuroendocrine tumor, well differentiated, low or intermediate grade | Australasian Gastro-Intestinal Trials Group | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | octreotate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02358356 ↗ |
| Modality | Peptide | “Lutetium-177 Octreotate (177Lu-Octreotate (Lutate)) peptide receptor radionuclide therapy (PRRT)” NCT02358356 ↗ |
| Route | Intravenous | “given intravenously (IV)” NCT02358356 ↗ |